Adalimumab biosimilar - Coherus BioSciences

Drug Profile

Adalimumab biosimilar - Coherus BioSciences

Alternative Names: CHS-1420

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Coherus Biosciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis

Most Recent Events

  • 31 Jan 2017 Coherus Biosciences files for petitions for Inter Partes Review of US patent 9 085 619 with USPTO
  • 10 Jan 2017 Top-line efficacy data from a phase III trial in Psoriasis released by Coherus Biosciences
  • 09 Nov 2016 Coherus BioSciences has patent protection for adalimumab biosimilar in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top